Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study.
Saved in:
| Title: | Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study. |
|---|---|
| Authors: | Chow V; Amgen Inc., Thousand Oaks, CA, USA., Winkle PJ; Anaheim Clinical Trials, Anaheim, CA, USA., Mytych DT; Amgen Inc., Thousand Oaks, CA, USA., Cao J; Amgen Inc., Thousand Oaks, CA, USA., Barragan C; Amgen Inc., Thousand Oaks, CA, USA., Colbert A; Amgen Inc., Thousand Oaks, CA, USA., Gupta S; Amgen Inc., Thousand Oaks, CA, USA., Radziszewski W; Amgen Inc., Thousand Oaks, CA, USA., Franklin J; Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2026 Feb; Vol. 15 (2), pp. e70031. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Comparative Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print Cited Medium: Internet ISSN: 2160-7648 (Electronic) Linking ISSN: 2160763X NLM ISO Abbreviation: Clin Pharmacol Drug Dev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
